close

Agreements

Date: 2016-01-05

Type of information: Nomination

Compound:

Company: Audentes Therapeutics (USA - CA)

Therapeutic area: Rare diseases - Genetic diseases

Type agreement:

nomination

Action mechanism:

Disease:

Details:

* On January 5, 2015, Audentes Therapeutics announced the appointment of Scott Morrison to its board of directors. Mr. Morrison will serve as chairman of the Audentes Therapeutics audit committee. Mr. Morrison was a Partner with Ernst & Young  from 1996 to December 2015, and served as its U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where he has also served on the audit committee since 2002. Mr. Morrison has previously served on the boards of directors of the Life Sciences Foundation, the Bay Area Biosciences Association and the Emerging Companies Section of the Biotechnology Industry Organization. Mr. Morrison received a B.S. in Accounting and Finance from the University of California-Berkeley.

Financial terms:

Latest news:

Is general: Yes